Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
29 03 2019
29 03 2019
Historique:
received:
04
12
2018
accepted:
15
03
2019
revised:
13
03
2019
entrez:
31
3
2019
pubmed:
31
3
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Calreticulin (CALR) exon 9 frameshift mutations, commonly detected in essential thrombocythemia (ET) and primary myelofibrosis patients, activate signal transducer and activator of transcription (STAT) proteins in the presence of Myeloproliferative Leukemia Virus (MPL) and induce ET in vivo. Loss of the KDEL motif, an endoplasmic reticulum retention signal, and generation of many positively charged amino acids (AAs) in the mutated C-terminus are thought to be important for disease induction. To test this hypothesis, we generated mice harboring a Calr frameshift mutation using the CRISPR/Cas9 system. Deletion of 19-base pairs in exon 9 (c.1099-1117del), designated the del19 mutation, induced loss of the KDEL motif and generated many positively charged AAs, similar to human mutants. Calr del19 mice exhibited mild thrombocytosis, slightly increased megakaryocytes, and mild splenomegaly. In vitro experiments revealed that the murine CALR del19 mutant had a weaker ability to combine with murine MPL than the human CALR del52 mutant. Consequently, STAT5 activation was also very weak downstream of the murine mutant and murine MPL, and may be the reason for the mild disease severity. In summary, loss of the KDEL motif and positively charged AAs in the C-terminus of CALR is insufficient for MPL binding and ET development.
Identifiants
pubmed: 30926777
doi: 10.1038/s41408-019-0202-z
pii: 10.1038/s41408-019-0202-z
pmc: PMC6440999
doi:
Substances chimiques
CALR protein, human
0
Calreticulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Références
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Leukemia. 2019 Jan;33(1):122-131
pubmed: 29946189
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
Blood. 2018 Feb 8;131(6):649-661
pubmed: 29282219
Blood. 2006 Jun 1;107(11):4300-7
pubmed: 16484588
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Leukemia. 2017 May;31(5):1136-1144
pubmed: 27807369
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Sci Rep. 2016 Aug 17;6:31666
pubmed: 27530713
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
PLoS Biol. 2013;11(6):e1001576
pubmed: 23750118
Cell. 1998 May 29;93(5):841-50
pubmed: 9630227
Blood. 2018 Feb 15;131(7):782-786
pubmed: 29288169
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Exp Hematol. 2011 Mar;39(3):351-359.e3
pubmed: 21185906
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187